Imagia Canexia Health (ICH), a genomics-based cancer treatment testing company that accelerates access to precision care by combining AI expertise with advanced molecular biopsy solutions, today announced that Health Canada now permits ICHIP—held under ICH’s Imagia Healthcare subsidiary—to be manufactured and deployed across Canada. Imagia Canexia Health offers a unique clinical solution for oncologists to quickly generate reports, which includes therapeutic and clinical trial recommendations. The ICHIP furthers their ability by providing intricate molecular and computational genome analysis, from targeted next-generation sequencing (NGS) data, for individual cancer patients. This new approval advances Imagia Canexia Health’s mission to combine groundbreaking genomics, oncology, artificial intelligence, and informatics so health systems can provide cost-effective testing in-house.

Clinicians receive next-generation sequencing (NGS) data sourced from human tissue or blood samples. These insights are collected, as well as processed, on Illumina’s NextSeq and MiSeq devices. Then, ICHIP uses AI to detect and analyze genomic variants, match interpretations, identify potential clinical trials, as well as generate a cancer-treatment results report to augment treatment decisions by oncologists. This information is used in conjunction with other clinical and diagnostic findings to make the most informed care-management decisions.

The ability to now implement ICHIP locally at our Cancer Center means clinicians will have a report informed by the clinical context, creating even more robust real-time-data insights to support their expertise,

said Dr. Bryan Lo, the Medical Director, Molecular Oncology Diagnostics Lab, at The Ottawa Hospital and Eastern Ontario Regional Laboratory Association, who is currently using ICH’s software to report out liquid biopsy cases.

Cancer is a constant fight against time, and novel technology like the ICHIP which helps make faster decisions is invaluable to our patients’ lives.

ICH is proud of our Health Canada Medical Device Establish License, as it is important for commercializing ICHIP, which can now be manufactured and distributed across the country,

said Imagia Canexia Health CEO Geralyn Ochab.

This milestone reinforces ICH’s commitment to having our products reach patients and improve Canadian’s lives.

About Imagia Canexia Health

Imagia Canexia Health (ICH) is a genomics-based cancer treatment testing company that accelerates access to precision care by combining AI expertise with advanced molecular biopsy solutions. Leveraging AI-based informatics for treatment selection and monitoring, oncologists now have leading clinical decision support right at their fingertips. With a network of over 20 hospitals and reference labs worldwide, ICH ensures that doctors have the right insights to deliver cost-effective cancer testing to patients no matter where they seek treatment. Join ICH in closing the health-equity gap in cancer: imagiacanexiahealth.com

Contact:
Peter Weltman
peter@mow.media
(415) 340-2040‬

Back

Recent Resources

Blog

August 30, 2022

CGC 2022 Key Takeaways

NGS Reporting, Whole Genome Sequencing, and In-House Testing major themes in this year’s meeting